Fresenius Kabi Launches Dexmedetomidine HCl Injection

Fresenius Kabi announced the launch of Dexmedetomidine Hydrochloride Injection, the generic version of Hospira‘s Precedex

Precedex is a selective alpha-2 adrenergic agonist. Approved by the FDA in September 2015, Dexmedetomidine Hydrochloride Injection is indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures.

RELATED: New Opioid Alternative Promising for Anesthesia Sedation

Dexmedetomidine Hydrochloride Injection is available in 200mcg (base) per 2mL single-dose vials.

For more information call (888) 386-1300 or visit